Phase III trial of TAK 875 in T2D meets primary endpoint

Phase III data on the compound TAK 875 (fasiglifam), from Takeda, a treatment for Type 2 diabetes, demonstrated the study's primary endpoint of change from baseline in HbA1c at week 24 was met. Study findings showed that fasiglifam significantly improved glycemic control with low incidence of hypoglycemia and statistically significant reductions in HbA1c, compared with placebo, at 24 weeks in patients with Type 2 diabetes inadequately controlled by diet and exercise.

The difference in the least-square means in HbA1c versus placebo was -0.75% in the fasiglifam 25 mg group and -1.01% in the fasiglifam 50 mg group. There were no significant differences in incidence of adverse events between the fasiglifam groups and the placebo group. Data were presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.